We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (TriKE ), and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. Our TriKE and Dual Targeting TriKE platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patients own natural killer cells (NK cells)....
Q2 FY2026 — expected 2026-09-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001493152-26-008443 | EDGAR | 63K words |
| 2025-02-21 | 2024-12-31 | 0001493152-25-007908 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001493152-24-011332 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009812 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001493152-22-007883 | EDGAR | — |
| 2021-04-16 | 2020-12-31 | 0001654954-21-004295 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001654954-20-003380 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001654954-19-003697 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001654954-18-002054 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001654954-17-002919 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-023400 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0001493152-25-011971 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010790 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045892 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032143 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019970 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0001493152-23-038957 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001493152-23-026973 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017492 | EDGAR | — |
| 2022-10-31 | 2022-09-30 | 0001493152-22-030019 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022629 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013539 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001493152-26-008442 | EDGAR | 3K words |
| 2025-11-26 | 0001493152-25-025162 | EDGAR | — |
| 2025-11-14 | 0001493152-25-022631 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015725 | EDGAR | — |
| 2025-09-23 | 0001493152-25-014684 | EDGAR | — |
| 2025-08-29 | 0001493152-25-012479 | EDGAR | — |
| 2025-07-24 | 0001641172-25-020847 | EDGAR | — |
| 2025-06-11 | 0001641172-25-014700 | EDGAR | — |
| 2025-05-27 | 0001641172-25-012481 | EDGAR | — |
| 2025-05-13 | 0001641172-25-009941 | EDGAR | — |
400 total filings indexed. 368 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000109657 |
| Ticker | GTBP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gtbiopharma.com |
| Listed | 2021-02-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GTBP (~200 tokens, structured JSON with cryptographic provenance)